Amarin Corp Plc (AMRN)

[sharinky]

Joel Beatty

Got it. So in the near-term, it sounds like manufacturing capacity is increasing quite a bit already. So what’s realistic in the longer term for Vascepa revenues? I think occasionally some of the highest estimates reach as high as let’s say $10 billion in revenue for Vascepa. Is that something that’s realistic? Is there a path to get there?

John Thero

We do hear those numbers and I have done or had various quantitative analysis done that have a range of scenarios that would include numbers in that ballpark. At this point in time, that’s not our guidance. We’ve only given guidance for this year. We don’t even have a label yet for cardiovascular risk reduction. We do think that’s the opportunity here is in multiple billions of dollars as to whether it’s, $10 billion or not. I think it’s a little premature to be providing guidance there. But this is a very large opportunity and we are positioning ourselves that if the demand is that high that we’ll get there.

Please also see AMarin's Q&A take on supply.

https://amarincorp.gcs-web.com/static-files/415bd347-0579-4897-bec9-a0e82d4f0380